Member Info for draft

Was impossible to buy on open Anyway should fly up more as market cottons on

Revenue £1.158 billion This deal is huuugeeeee

Should easily be even more This is the biggest deal EVER

New e-tailer distribution deal � The Company is pleased to announce it has secured a distribution deal with ASOS plc for Skinny Tan.� � ASOS plc ("ASOS"), is one of the largest global online fashion and beauty store attracting hundreds of millions of visitors in the UK and internationally on its website. Skinny Tan will be available through ASOS's website from June and will be marketed and distributed globally by ASOS. � The Company continues to open up new markets worldwide especially in continental Europe for its fast-growing Skinny Tan brand through securing e-tailers which offer European and worldwide delivery. � Trading continues to be very robust and revenue growth has continued on its positive momentum with April acheiving the highest-ever monthly revenue. � Separately, the Company is pleased to announce it is a finalist for the IPO of the Year award at the Small Cap Awards to be held on 22 June 2017. �

Major Asos deal wow

about 6%. Ill top up if this comes back to my average of 3.5p

the 90% rise before is just a taster of what is to come here no shares free, and massive contract wins

little shares in free float now - could see a rapid climb up

news here soon

we might hear anything

why anyone thinks the products are poor?

these guys don't rns much! I wonder what has happened since then

the fact I'm the only person posting on here tells me I am going to 5-10 bag on this - the quieter shares always win limited free float and blue sky investments pis going to regret not being in this one I think.

Clontarf Energy plc is an emerging oil and gas, exploration and production, company focused on South America and Africa. The company’s experienced team has a successful track record in exploration. In 2010 it returned $32 million to its shareholders when it sold off Pan Andean Resources; Clontarf’s predecessor in South America. Clontarf Energy is listed on AIM (Ticker: CLON)

think I need to read the rnss

On 16 December 2016, Work Group announced that it had entered into an agreement for the potential acquisition of a group of companies in the business services sector which would constitute a reverse takeover under the AIM Rules for Companies (the "Acquisition"). Work is ongoing on the Acquisition and the Company and its advisers are seeking to complete the Acquisition, subject to shareholder approval, as soon as possible. Until binding terms are agreed, there is no guarantee that the Acquisition will ultimately proceed. Further updates will be provided in due course.

this is painful waiting for this

about 2million euros and this will fly to 10p plus I think

new NED is going to secure some big contracts in my opinion The Fresenius Group is made up of four divisions (a publicly traded company of which Fresenius owns 30.8%):[4] Fresenius Medical Care focuses on patients with chronic kidney failure Fresenius Helios is Germany’s largest hospital operator Fresenius Kabi is a supplier of essential drugs, clinical nutrition products, medical devices Fresenius Vamed plans, develops and manages healthcare facilities.

Vinod Kaushal Vinod is a non-executive director on the board of Flying Brands plc. Vinod is a well-seasoned healthcare industry executive with nearly 30 years' experience in predominantly commercial and general management roles. He has worked nationally, regionally and globally for a number of blue chip and SME companies. Having been part of the team which orchestrated the international launch of Losec®/Prilosec® at Astra to its place as the global No. 1 selling pharmaceutical, Vinod was Head of Global Marketing at Novo Nordisk, Senior Vice President Fresenius Kabi, Vice President of Amersham/GE Health's Neurology business, Vice President at Royal Numico/Danone and CEO of SPL amongst other pivotal roles. Since leaving Big Pharma, Vinod has recently been focused on entrepreneurial activities with a number of successful SMEs in the Pharma/Healthcare space. With an impressive deal sheet to his name, Vinod has been involved in various IP and business acquisitions. His career has seen him relate to investors on several global stock exchanges and he is an accomplished external speaker. Vinod holds a BSc (Hons) in Biochemistry from Warwick University and a MBA from Henley Business School.